The endocrine system regulates metabolism through a network of hormones, receptors, and feedback loops. When these pathways are activated or modulated, the body adjusts how it stores fat, releases energy, and distributes adipose tissue. Three peptides have become the focus of significant research interest for the roles they appear to play in metabolic signaling.
Retatrutide
What it is: A triple-receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. In a Phase 3 clinical trial, Retatrutide simultaneously targets three receptor pathways (GLP-1, GIP, and glucagon), making it one of the most closely watched metabolic peptides in current research. Source
How It Works
What Researchers Study It For
Common Research Protocols
Retatrutide is currently under clinical investigation as a subcutaneous injection. Research protocols are defined within the context of ongoing clinical trials. Source
Community Interest Areas
The research community has shown intense interest in Retatrutide due to its triple-agonist mechanism, which distinguishes it from dual-agonist compounds like tirzepatide. Its ability to engage the glucagon receptor in addition to GLP-1 and GIP pathways has generated particular attention in metabolic research circles focused on energy expenditure.
Tesamorelin
What it is: A synthetic analog of GHRH (growth hormone-releasing hormone) consisting of 44 amino acids. In a 404-patient clinical trial, Tesamorelin demonstrated statistically significant reductions in visceral adipose tissue. Source
How It Works
What Researchers Study It For
Common Research Protocols
Tesamorelin is reconstituted from lyophilized powder and administered via subcutaneous injection. Source
Community Interest Areas
Tesamorelin draws significant research interest for its specificity toward visceral adipose tissue rather than subcutaneous fat. The research community has explored it extensively in body composition studies, particularly in contexts where visceral fat accumulation is a primary variable. Its mechanism of stimulating endogenous GH release, rather than introducing exogenous GH, is a key point of differentiation.
AOD 9604
What it is: A modified fragment of human growth hormone, specifically amino acids 177–191 with a tyrosine addition. It was designed to isolate the fat-metabolizing activity of growth hormone without its growth-promoting or diabetogenic effects. Source
How It Works
What Researchers Study It For
Common Research Protocols
AOD 9604 is typically reconstituted from lyophilized powder with bacteriostatic water and administered via subcutaneous injection. In preclinical studies, it has been investigated in both oral and injectable formats. Research dosing varies by study design, with many protocols exploring fasted-state administration to maximize lipolytic activity. Source
Community Interest Areas
AOD 9604 draws research interest for its targeted approach to fat metabolism. Because it is a fragment of growth hormone rather than the full molecule, researchers study it as a way to isolate lipolytic effects without influencing blood sugar or stimulating tissue growth. It is frequently explored in combination with other metabolic peptides in multi-pathway protocols.
How They Compare
Key Takeaways
- Retatrutide is a triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, the first compound studied across all three pathways simultaneously
- Tesamorelin stimulates endogenous growth hormone release via the GHRH receptor, with clinical research demonstrating selective reduction of visceral adipose tissue in a 404-patient trial
- AOD 9604 isolates the lipolytic fragment of growth hormone to promote fat breakdown without growth-related or diabetogenic effects
- Each peptide approaches metabolic signaling through a different mechanism, reflecting the multiple pathways the body uses to regulate energy storage and expenditure
- The statements made on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). All products sold by 33 Degrees of Healing are provided strictly for research, laboratory, and investigational purposes only.
Related Research Compounds
Read the Full Scientific Review →
Sources
- Eli Lilly. Retatrutide clinical trial program. ClinicalTrials.gov. ClinicalTrials.gov
- Falutz J, et al. Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients. JAMA. 2010. PubMed
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001. PubMed
- Coskun T, et al. Retatrutide, a triple incretin receptor agonist, for obesity. N Engl J Med. 2023. PMC
This article is for educational and research purposes only. It is not intended as medical advice. The compounds discussed are research chemicals not approved by the FDA for human use. Always consult qualified professionals and review current regulations before conducting any research.